Search
Talc
go.drugbank.com/drugs/DB09511ApprovedInvestigationalIt is a substance often found in cosmetic and personal hygiene products including baby powder, adult body powders and facial powders. … Talc is a mineral composed primarily of magnesium, silicon and oxygen.
Mixtures: Face It Hd Perfect Bb Spf30 Pa 02, Face It Hd Perfect Bb Spf30 Pa 01Categories: Compounds used in a research, industrial, or household settingHydralazine
go.drugbank.com/drugs/DB01275ApprovedInvestigational[A186820,L8782,L8785] Hydralazine is no longer a first line therapy for these indications since the development of newer antihypertensive medications. … [A186841] Hydralazine is a hydrazine derivative vasodilator used alone or as adjunct therapy in the treatment of hypertension and only as adjunct therapy in the treatment of heart failure.
Categories: Arteriolar Smooth Muscle, Agents Acting OnEucalyptus oil
go.drugbank.com/drugs/DB11114ApprovedEucalyptus oil is a distilled oil derived from the leaves of the tree Eucalyptus. … It is shown to be effective in reducing pain, swelling, and inflammation via its modulatory effect on the immune response.
Mixtures: La Vaquita, La Vaquita Extra StrengthFerrous gluconate
go.drugbank.com/drugs/DB14488ApprovedInvestigationalSynonyms: Iron(II) gluconate, anhydrous, D-gluconic acid, iron(2+) salt (2:1)Mixtures: Iron II, Alsimine W Vitamins A DLorlatinib
go.drugbank.com/drugs/DB12130ApprovedInvestigationalinclude lorlatinib as a first-line treatment option in advanced ALK-positive NSCLC. … Lorlatinib is a third-generation ALK tyrosine kinase inhibitor (TKI) for patients with ALK-positive metastatic non-small cell lung cancer[L39905] which was first approved by the US FDA in November of 2018
Lurasidone
go.drugbank.com/drugs/DB08815ApprovedInvestigationalFood and Drug Administration (FDA) for treatment of schizophrenia on October 29, 2010 and is currently pending approval for the treatment of bipolar disorder in the United States. … Lurasidone is an atypical antipsychotic developed by Dainippon Sumitomo Pharma. It was approved by the U.S.
Categories: Dopamine D2 Receptor AntagonistsCangrelor
go.drugbank.com/drugs/DB06441ApprovedInvestigationalCangrelor was approved by the FDA in June 2015 for intravenous application. … An advantage Cangrelor provides over oral P2Y12 inhibitors (such as prasugrel, ticagrelor, and clopidogrel) is that it is an active drug not requiring metabolic conversion therefore providing a rapid onset
Moxonidine
go.drugbank.com/drugs/DB09242ApprovedInvestigationalWithdrawnIt is suggested to be effective in cases where other agents such as thiazides, beta-blockers, ACE inhibitors, and calcium channel blockers are not appropriate or irresponsive. … Moxonidine is a new-generation centrally acting antihypertensive drug approved for the treatment of mild to moderate essential hypertension.
Products: MOXONIDIN 1A PHARMA 0.2MG, MOXONIDIN 1A PHARMA 0.3MGManganese gluconate
go.drugbank.com/drugs/DB11141ApprovedManganese gluconate is a direct ingredient in food substances as a nutrient supplement. In pharmaceutical preparations it is used as a [DB06757] supplement. … It is typically obtained by reacting manganese carbonate with gluconic acid in aqueous medium and then crystallizing the product to form a slightly pink powder.
Synonyms: Manganese(II) gluconate, Manganese D-gluconateMixtures: Cal-mag Plus K, Mn and Zn Caplets, Vitamin E 400 Iu With Selenium, Vitamin C & ManganeseIbrutinib
go.drugbank.com/drugs/DB09053ApprovedInvestigationalIt is designated as a targeted covalent drug and presented as a promising activity in B-cell malignancies in clinical trials. … Ibrutinib is a small molecule that acts as an irreversible potent inhibitor of Burton's tyrosine kinase.
Synonyms: 1-[(3R)-3-[4-Amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]piperidin-1-yl]prop-2-en-1-one